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Results 
Socio-economic burden 
•  On average annual cost of MS per patient in France was estimated at €24,403 
(±18,538) (Figure 1).  
•  57% of total costs (€13,838, ±15,796) accounted for indirect costs due to 
productivity losses and 36% (€8,877, ±8,497) and 7% (€1,686, ±4,309) accounted 
for mean, annual direct medical and non-medical costs respectively.  
•  Indirect costs were primarily driven by permanent work disability (€7,701 
±14,727) and temporary sick leave (€3,091 ±7,101), corresponding to 42% and 
12% of mean annual costs respectively).  
•  Direct costs were shaped by DMD utilisation (€7,609 ±8,271),formal/informal 
caregiving (i.e. direct non-medical costs) (€1,686, ±4,309) and ambulatory/inpatient 
care (€1,267±1,414) (i.e. 31%, 7% and 5% of mean annual cost respectively).  
•  Average annual cost per patient amounted up to €31,514 (±23,400) for individuals 
with Primary Progressive MS (PPMS), €27,664 (±22, 992) for those with 
Secondary Progressive MS (SPMS) and €24,261 (±17,775) for those with 
Relapsing Remitting MS (RRMS) (Figure 1).  
v Indirect costs due to productivity losses accounted for 72% (€22,684), 
80% (€22,233) and 49.7% (€12,075) of the above total costs respectively. 
•  Statistically significant differences (p<0.05) were observed between all cost 
categories across types of MS apart from inpatient and formal care costs.  
HRQoL  
•  Mean EQ-5D-5L index and VAS scores were 0.49 (±0.3) and 60.5 (±22) 
respectively, whereas the Barthel index score reflected that overall the sample was 
mildly dependent (i.e. 15-19) in carrying out their daily activities (Table 1).  
•  HRQoL (EQ-5D-5L index and EQ-5D-5L VAS) and Barthel Index outcomes 
fluctuated between the different types of MS, with statistically significant 
(p<0.001) differences observed between groups in EQ-5D-5L utility, utility loss and 
Barthel Index scores (Table 1). 
Experience with MS  
•  Overall, a moderate satisfaction (7.4 out of 10) was observed with the health care 
received by the national health system and this dropped to 6.6 for individuals with 
PPMS, although no statistically significant differences were observed between  
types of MS (Table 1).  
•  An unmet need to receive formal/informal care was reported by 7% of respondents 
and an unmet need for a new therapy that targets  of Mobility and Fatigue/
Weakness (43% and 40% of respondents respectively) among others (Figure 3). 
•  MS websites are the preferred sources of information for individuals with MS (48% 
of respondents) while 4% of individuals have not looked for information (Figure 2). 
Methods 
•  Data collection was based on a web-survey (Qualtrics ®) of non-institutionalised individuals with MS.   
•  Three patient associations (either national or supranational) were invited to cascade the surveys to their network of patients. 
•  Data were collected on i) demographic, ii) disease and clinical related variables, iii) Disease Modifying Drug (DMD) consumption, iv) healthcare 
resource and informal care utilisation, v) productivity losses, vi) QoL (EuroQoL 5-domain; EQ-5D-5L), EQ-5D-5L VAS and vii) Physical disability 
(Barthel Index). 
•  In addition, the survey gauged patients’ experience with MS through questions on i) treatment satisfaction, ii) future treatment expectations, iii) 
caregiving arrangements and iv) preferred sources of information for MS.  
•  Microsoft® Excel 2010 was used to generate descriptive statistics and SPSS   (v.21) to test for treatment group differences (using one way ANOVA and 
independent samples t-test). 
Background & Objectives 
Multiple Sclerosis (MS) is the second most common cause of neurological disability 
and highest per capita costs among all other neurological disorders [1]. Even though 
France has the lowest prevalence rates among other north European countries (94.7 per 
100.000) [2], in 2009 the total annual cost per patient was estimated at €44,400, 
translated in an estimated total cost of €1.3 billion per year for MS in France [3].  
 
v Due to the advances observed in Disease Modifying Therapies (DMTs) for MS 
since 2012 (such as the approval of the oral agents Dimethyl fumarate and 
Fingolimod) which might imply higher direct costs but also higher efficacy and 
compliance rates [4, 5], we aimed to provide an updated analysis on the 
socioeconomic burden, Health Related Quality of Life (HRQoL) and experience of 
MS patients in France. 
Conclusions & Future directions 
MS poses a significant cost burden for the French society, with medication and  
indirect costs representing 88% of total average costs and substantial unmet needs  
being reported in the clinical management and social care currently received by  
MS patients in France. 
v  In the absence of long-term, real world data about the cost-effectiveness of 
receiving DMT earlier in the course of the disease, when to initiate treatment 
and which DMT to use are still to be determined.  
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Figure 3. Aspects that a potentially new treatment should keep under control according to individuals with MS  
(% of respondents, n=97)    
 All sample (n=92) 
RRMS 
(n=50) 
SPMS 
(n=7) 
PPMS 
(n=11) 
Unknown type 
(n=24) 
EQ-5D-5L Utility 0.48 (0.28)*           0.55 (0.24) 0.23 (0.32) 0.32 (0.37) 0.49 (0.23) 
Utility loss 0.34 (0.28)* 0.27 (0.24) 0.6 (0.32) 0.51 (0.37) 0.33 (0.23) 
EQ-5D-5L VAS 60.5 (22) 65.2 (21) 46 (25.2) 50.9 (21.3) 59 (22) 
Barthel index 17.5 (3.3)* 18.6 (1.9) 14.3 (4.5) 14.4 (4.6) 17.4 (3.3) 
Treatment satisfaction 7.4 (2.3) 7.6 (2.2) 7.7 (3.0) 6.1 (2.8) 7.4 (1.7) 
Table 1. Sample HRQoL characteristics [mean (SD)] and statistical significance (p) of differences between type of 
MS groups.  
*p<0.001 
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